Viz.ai, provider of AI-powered disease detection and care coordination tools, has announced a multi-year agreement with Bristol Myers Squibb, a global biopharmaceutical company.
The partnership will deploy an artificial intelligence (AI) algorithm and provider workflow software intended to identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy (HCM).
HCM is defined by thickened heart muscle, which can make it harder for the heart to pump blood. It is associated with increased risks of atrial fibrillation, mitral valve disease, and heart failure. HCM is estimated to impact an estimated 750,000 people in the United States and 20 million worldwide.
Viz.ai has submitted a de novo request to the U.S. Food and Drug Administration (FDA) for the algorithm as a Software-as-a-Medical-Device (SaMD), and the filing has been accepted by the agency for review.
The tool, Viz HCM, is intended to automatically review routine electrocardiograms (ECGs) from across a health system, identify suspected cases of HCM, and notify the appropriate cardiologist. The physician can then review the ECG in a timely manner and take the appropriate clinical action, including recommending follow-up diagnostic testing in parallel to the standard of care.
Viz HCM will be integrated into the Viz.ai Cardio Suite for U.S. hospitals, which is expected to advance cardiac care coordination through a mobile-based electrocardiogram viewer, built with timely AI-powered alerts and communication tools.
The company plans to launch Viz HCM broadly upon FDA clearance.
Click here to read the original news story.
Looking for expert insights in Virtual Care Delivery? Join the HealthXL Masterclass on ‘Current State of Routes to Market in Digital Health’ on 28th March. Click here to Request to Join.